Semaglutide in Children Ages 6–11: The Clinical Breakthrough — and the Questions We Now Have to Answer
On September 7, 2026, Novo Nordisk reported topline Phase 3 results from STEP Young — a trial of semaglutide in children aged 6 to under 12 with obesity.
The headline result is striking. The questions it raises are equally important.
What STEP Young Found
Trial: STEP Young — Phase 3, randomized, controlled Population: 165 children aged 6 to under 12 with obesity Duration: 68 weeks of semaglutide plus lifestyle modification vs. placebo plus lifestyle modification Primary endpoint: Percent change in BMI from baseline to week 68 — met, with superior BMI reduction on semaglutide versus placebo
Key finding: 40.4% of children receiving semaglutide were no longer classified as having obesity at 68 weeks.
Placebo comparison: none of the placebo group achieved this outcome.
Baseline: More than 85% of enrolled children had severe Class II or III obesity at the start of the trial.
Tolerability: Novo Nordisk states the overall safety and tolerability were consistent with previous paediatric and adult semaglutide trials, with no new safety concerns, and that no safety concerns were identified for growth or pubertal development. Detailed results will be presented at ObesityWeek 2026, November 14–17, Washington, DC.
Source: Novo Nordisk company announcement, September 7, 2026 (GlobeNewswire).
Important caveat: These are topline company results, not the complete published dataset. The full safety profile, subgroup analyses, body composition data, and secondary endpoints will be presented at ObesityWeek in November. We are not yet working from a peer-reviewed publication.
Why This Is a Genuine Clinical Breakthrough
Severe obesity in childhood carries consequences that extend far beyond the scale. Cardiometabolic risk factors established in childhood — elevated blood pressure, insulin resistance, dyslipidemia — tend to track into adulthood. Severe Class II and Class III obesity in a 6-year-old represents a disease state with lifelong implications.
For decades, the therapeutic options in this age group were limited to lifestyle modification and, in extreme cases, bariatric surgery. Lifestyle-only interventions have consistently shown limited efficacy in severe pediatric obesity. The absence of effective pharmacologic tools has been a real clinical problem.
The STEP Young finding — 40.4% of children achieving reclassification out of obesity vs. 0% on placebo — represents the kind of effect size that changes clinical practice. If confirmed in the full dataset, this is meaningful.
Semaglutide has been approved for adolescents (12+) since December 2022 on the strength of STEP TEENS — 201 adolescents, BMI change −16.1% on semaglutide versus +0.6% on placebo at 68 weeks. STEP Young extends the evidence base to younger children. That extension is not trivial — the biology, psychology, and developmental considerations at age 6-11 are genuinely different from adolescence.
The Questions This Breakthrough Immediately Raises
A result this dramatic in a vulnerable population requires careful thinking about what comes next. These are not objections to the finding — they are the necessary scientific questions that any responsible clinical program must now answer.
1. How long do children stay on therapy?
Semaglutide is not a cure. It manages a chronic condition while being taken. The post-cessation data from adult trials is consistent: weight returns when the drug stops, and it returns fat-preferentially. In an 8-year-old, the question of "how long is the treatment duration" carries different weight than in a 45-year-old.
If a child starts semaglutide at age 6, achieves reclassification out of obesity by age 7.5, and then stops — what happens? Does the obesity return? At what rate? What does the body composition look like?
These questions don't have answers yet for this age group.
2. What happens to growth and puberty?
Children ages 6-11 are approaching puberty. GLP-1 receptors are expressed in tissues beyond the gut and pancreas. The long-term effects of semaglutide on growth hormone signaling, pubertal development, and bone density in pre-pubertal children have not been established through long-term trials.
Novo Nordisk's release states that no safety concerns were identified for growth or pubertal development in STEP Young. That is a company topline statement, not yet published data, and a 68-week window does not capture what happens through puberty.
3. What does body composition look like — not just BMI?
The primary endpoint in STEP Young was reclassification out of obesity, which is BMI-based. In adults, lean-mass losses averaging 6–7 kg have been reported during active incretin treatment (Zeigler et al., 2026 narrative review). In a growing child, the distinction between fat loss and lean mass changes is particularly important.
A child losing weight on semaglutide who also loses significant skeletal muscle mass is in a meaningfully different situation than one who loses fat while preserving or building lean tissue. The body composition question needs to be answered in this age group.
Novo Nordisk has stated detailed results will be presented in November. Hopefully that includes DEXA or InBody-equivalent body composition data.
4. What are the family and behavioral dynamics?
Childhood obesity rarely develops in isolation. Family eating patterns, food environment, physical activity, sleep, and socioeconomic factors all contribute. Pharmacologic treatment that achieves reclassification out of obesity without addressing these underlying factors may not produce durable change.
The trial included lifestyle modification alongside semaglutide — but what does that look like in practice, and what happens to behavioral patterns when a child's appetite is pharmacologically suppressed during critical developmental years?
5. What is the long-term safety profile over years, not months?
68 weeks is approximately 16 months. That's meaningful for an efficacy signal. For a child who might be on therapy for 5, 10, or 20 years, it's a very short safety window. The STEP Young trial cannot tell us about 10-year outcomes for organs that are still developing.
Whether and how long to treat is a decision for the child's clinicians and family. What the evidence base needs, as this treatment is deployed, is careful tracking, systematic monitoring, and a longitudinal record that outlasts the trial.
What This Means for GLP-1 2.0
The STEP Young result reinforces the central argument of GLP-1 2.0: weight loss is Chapter One, not the whole story.
In an adult with established obesity, questions about body composition, maintenance, and long-term safety are important. In a child during active development, they become urgent.
STEP Young is exactly the kind of development that makes that infrastructure not optional but essential. A 6-year-old starting semaglutide needs:
- Body composition monitoring (not just scale weight)
- Growth and developmental tracking
- Nutritional adequacy monitoring (adequate protein and micronutrients despite appetite suppression)
- Behavioral and family support
- A clear plan for what happens at the transition out of treatment
That's a tracking and monitoring problem. Not just a prescription problem.
The Bottom Line
STEP Young is a genuine clinical breakthrough. 40.4% of children with severe obesity achieving reclassification out of obesity over 68 weeks — against 0% on placebo — is a meaningful result that will change how pediatric obesity is treated.
It also opens a set of questions about duration, growth, body composition, behavioral dynamics, and long-term safety that will take years to answer.
The drug works in this population. Now the field has to build the infrastructure to use it responsibly.
Full data in November. We'll cover it.
→ Follow the latest at PeptidesGPT.com/research
Sources:
- Novo Nordisk. "Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification." Company announcement, September 7, 2026.
- Weghuber D, et al. "Once-Weekly Semaglutide in Adolescents with Obesity." N Engl J Med. 2022;387(24):2245–2257. PMID 36322838. DOI 10.1056/NEJMoa2208601.
- Zeigler Z, et al. "Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review." Healthcare (Basel). 2026;14(15). PMID 42588312. DOI 10.3390/healthcare14152345.
PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical advice. Decisions about medication for children should be made with a licensed pediatric healthcare provider.
Keep reading with The Peptides Brief
One email a week on what the evidence actually says. No dosing, no hype.